在董事会、监事会换届选举工作完成前，公司第十届董事会及第 十届监事会全体成员、高级管理人员将严格按照法律、行政法规和《公 司章程》等相关规定继续履行相应的职责和义务。 证券代码：600129 证券简称：太极集团 公告编号：2024-031 重庆太极实业（集团）股份有限公司 关于董事会及监事会延期换届的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会及第十届监事会已届满。鉴于公司换届选举工作仍在筹备中， 为保证公司董事会、监事会工作的连续性及稳定性，公司董事会、监 事会的换届选举工作将延期进行，公司第十届董事会各专门委员会及 高级管理人员的任期亦将相应顺延。 公司董事会、监事会延期换届不会影响公司正常运营。公司将积 极推进换届工作，并及时履行信息披露义务。 特此公告。 重庆太极实业（集团）股份有限公司 2024 年 6 月 28 日 ...

证券代码：600129 证券简称：太极集团 公告编号：2024-028 二、药品其他相关信息 青霉素 V 钾片的抗菌谱较广，主要用于治疗青霉素 G 敏感菌引起的轻 度到中度感染。治疗根据细菌学研究(包括药敏实验)和临床用药反应为指 导。以下感染通常会对足够剂量的青霉素 V 产生应答： 链球菌感染（无菌血症）：轻至中度上呼吸道感染、猩红热及轻度丹 毒。注：A、C、G、H、L、M 型链球菌对青霉素非常敏感。但其他类型对青 霉素有耐药性，其中包括 D 型（肠球菌）。 肺炎球菌感染：轻中度呼吸道感染。 葡萄球菌感染-青霉素 G 敏感：轻度皮肤和软组织感染。注：有报告表 明对青霉素 G 有耐药性的葡萄球菌菌株数量不断增多，在治疗疑似葡萄球 菌引起的感染时，细菌培养和药敏实验十分有必要。 重庆太极实业（集团）股份有限公司 关于青霉素 V 钾片通过仿制药一致性评价的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司）控股 子公司西南药业股份有限公司（以下简称：西南药业）收到国家药 ...

重庆源伟律师事务所 关于重庆太极实业（集团）股份有限公司 2023年年度股东大会的法律意见书 致:重庆太极实业（集团）股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和 国证券法》(以下简称"《证券法》")、中国证券监督管理委员会发布的《上市公 司股东大会规则》和《上海证券交易所上市公司自律监管指引第1号--规范运作》等 法律、法规、规范性文件以及《重庆太极实业（集团）股份有限公司章程》（以下 简称"《公司章程》"）的规定，重庆源伟律师事务所(以下简称"本所")接受重 庆太极实业（集团）股份有限公司(以下简称"公司")的委托，指派谢申丽、陈赓 律师出席公司于2024年5月16日14点00分在重庆市渝北区恒山东路18号公司1201楼 会议室召开的2023年年度股东大会(以下简称"本次股东大会")，对本次股东大会 的召集、召开程序、召集人和出席会议人员资格、会议表决方式和程序以及会议决 议的有效性等事宜出具法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审查， 查阅了本所律师认为出具法律意见所必须的文件、资料，并对有关事实进行了必要 的核查和验证。 ...

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 234 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 197,830,096 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 35.524 | 证券代码：600129 证券简称：太极集团 公告编号：2024-026 重庆太极实业（集团）股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事会召集，董事长李阳春先生主持，本次会议的召集、召 开及表决方式均符合《公司法》及《公司章程》的有关规定。 1 (一) 股东大会召开的时间：2024 年 5 月 16 日 (二) 股东大会召开的地点：重庆市渝北区恒山东路 18 号公司 1201 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 4,207,673,289.91, representing a decrease of 4.96% compared to the same period last year[4]. - Net profit attributable to shareholders of the listed company was CNY 246,838,634.18, an increase of 5.05% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 218,326,297.33, down by 8.47% compared to the previous year[4]. - Total operating revenue for Q1 2024 was approximately ¥4.21 billion, a decrease of 4.7% compared to ¥4.43 billion in Q1 2023[18]. - Net profit for Q1 2024 was approximately ¥249.14 million, an increase of 5.3% from ¥236.60 million in Q1 2023[19]. - The total comprehensive income for Q1 2024 was approximately ¥249.14 million, compared to ¥236.58 million in Q1 2023, indicating a growth of 5.3%[20]. Cash Flow - The net cash flow from operating activities was negative at CNY -166,876,620.52, indicating a significant cash outflow[4]. - Cash inflow from operating activities in Q1 2024 was approximately ¥3.51 billion, a decrease of 12.2% from ¥3.99 billion in Q1 2023[21]. - The net cash flow from operating activities for Q1 2024 was -$166.88 million, slightly improved from -$167.57 million in Q1 2023[22]. - Total cash outflow from operating activities decreased to $3.68 billion in Q1 2024 from $4.17 billion in Q1 2023, indicating a reduction of approximately 11.7%[22]. - Cash inflow from investment activities was $1.69 million in Q1 2024, down from $54.16 million in Q1 2023, representing a decline of about 96.9%[22]. - The net cash flow from investment activities was -$203.57 million in Q1 2024, compared to -$162.16 million in Q1 2023, reflecting a worsening of approximately 25.6%[22]. - Cash inflow from financing activities decreased to $190.65 million in Q1 2024 from $267.42 million in Q1 2023, a decline of about 28.7%[22]. - The net cash flow from financing activities improved to -$83.34 million in Q1 2024 from -$288.29 million in Q1 2023, indicating a significant improvement[22]. - The total cash and cash equivalents at the end of Q1 2024 were $1.20 billion, down from $1.35 billion at the end of Q1 2023, a decrease of approximately 11.5%[23]. - The total cash outflow for taxes paid decreased to $354.73 million in Q1 2024 from $455.32 million in Q1 2023, a reduction of about 22.1%[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 15,372,286,773.55, an increase of 6.66% from the end of the previous year[5]. - The total current assets reached ¥8,479,353,480.16, compared to ¥7,604,664,368.90 in the previous period, indicating an increase of about 11.48%[15]. - The total liabilities increased to ¥11,381,761,988.70 from ¥10,665,932,484.04, representing a growth of around 6.71%[16]. - The company's equity attributable to shareholders reached ¥3,869,350,003.73, up from ¥3,622,185,106.00, which is an increase of about 6.83%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,073[7]. - The company reported a total of 4,723,808 shares held by major shareholders, with a proportion of 0.85%[12]. Expenses - Research and development expenses increased to approximately ¥55.89 million in Q1 2024, up 47.0% from ¥38.03 million in Q1 2023[18]. - Sales expenses decreased to approximately ¥1.39 billion in Q1 2024, down 16.1% from ¥1.66 billion in Q1 2023[18]. - The company experienced a decrease in tax expenses, which were approximately ¥43.94 million in Q1 2024, down from ¥47.74 million in Q1 2023[19]. - The cash paid to employees increased to $509.95 million in Q1 2024 from $487.45 million in Q1 2023, an increase of approximately 4.0%[22]. Other Income - The company reported a significant increase in other income, which rose to approximately ¥42.47 million in Q1 2024, compared to ¥5.30 million in Q1 2023[18]. Earnings Per Share - The basic earnings per share for the period was CNY 0.44, reflecting a year-on-year increase of 4.76%[4]. - Basic earnings per share for Q1 2024 was ¥0.44, compared to ¥0.42 in Q1 2023, reflecting a 4.8% increase[20]. Asset Changes - Accounts receivable rose significantly to ¥2,637,196,340.70 from ¥1,978,057,763.16, marking an increase of approximately 33.33%[14]. - The inventory increased to ¥2,988,493,343.38 from ¥2,690,632,474.71, reflecting a growth of about 11.09%[15]. - The cash and cash equivalents decreased to ¥1,457,697,504.88 from ¥1,935,008,857.17, a decline of approximately 24.66%[14]. Strategic Developments - The company has not reported any new strategies or significant changes in product development during this quarter[13].

Financial Performance - The company achieved operating revenue of 15.62 billion yuan in 2023, representing a year-on-year increase of 10.58%[24]. - Net profit attributable to shareholders reached 822.12 million yuan, a significant increase of 131.99% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 774.45 million yuan, reflecting a year-on-year growth of 111.35%[24]. - Basic earnings per share were 1.48 yuan, up 131.25% from 0.64 yuan in 2022[18]. - The weighted average return on equity increased to 23.82%, compared to 12.15% in the previous year[18]. - The company reported a total revenue of 16,600 million for the year, with a net profit of 1,310.43 million[113]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 20% year-over-year growth[116]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a 15% year-over-year growth[117]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 3.0 CNY per 10 shares to all shareholders, totaling approximately 167.07 million CNY (including tax) based on a total share capital of 556,890,744 shares as of December 31, 2023[4]. - The company has held two shareholder meetings during the reporting period, ensuring equal voting rights for all shareholders[103]. - The company is committed to maintaining the interests of minority shareholders and has made amendments to its articles of association to enhance governance[103]. - The total number of ordinary shareholders as of the end of the reporting period was 26,909, down from 38,422 the previous month[199]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the authenticity and completeness of the financial report[3]. - The company is committed to ensuring the accuracy and completeness of the annual report, with management taking legal responsibility for its content[2]. - The company has not violated any regulatory decision-making procedures for external guarantees[6]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[105]. Risk Management - The company has outlined potential risks and corresponding countermeasures in the annual report management discussion and analysis section[6]. - The company faces significant risks from policy changes in the pharmaceutical industry, including centralized procurement and healthcare reforms, which may impact revenue and profit[101]. - The company is addressing market risks by improving its competitive capabilities and optimizing supply chain management[102]. Research and Development - The company launched 31 key R&D projects in 2023, including 16 traditional Chinese medicine projects, 14 chemical drug projects, and 1 biological drug project[31]. - The company has established strategic partnerships with over 20 universities and research institutions to enhance innovation and R&D capabilities[31]. - The company is focusing on R&D for anti-tumor, cardiovascular, and endocrine system drugs, while managing the risks associated with new drug development[102]. - Research and development expenses surged by 113.52% to approximately ¥233.62 million, compared to ¥109.42 million in the previous year, reflecting a significant increase in R&D investment[39]. Market Expansion and Strategy - The company expanded its international business, entering five new markets including the UAE and Italy, and obtained 21 relevant import/export certificates[27]. - The company aims to enhance its market presence in Southeast Asia, targeting a 20% increase in sales from this region[113]. - The company plans to enhance its digital marketing efforts, with an investment of 101.44 million aimed at increasing online sales channels[113]. - The company plans to establish at least 50 new key supplier partnerships and expand its direct sales pharmacy model by adding no less than 100 new franchise pharmacies in 2024[96]. Corporate Governance - The board of directors consists of 15 members, with 12 external directors and 5 independent directors, ensuring a majority of external and independent oversight[104]. - The company has established a long-term mechanism to prevent the controlling shareholder from occupying the company's funds and harming its interests, with specific provisions in the Articles of Association regarding "occupation equals freezing"[104]. - The company has implemented a communication mechanism with the controlling shareholder to ensure timely information disclosure[104]. Environmental and Social Responsibility - The company invested a total of 4,909,000 CNY in poverty alleviation and rural revitalization projects, benefiting 240,000 people[169]. - The company has established an environmental protection management system and developed emergency response plans for environmental incidents[163]. - The company achieved a reduction of 13,723 tons in carbon dioxide equivalent emissions through various decarbonization measures[164]. Financial Management - The company has established a comprehensive budget management system for subsidiaries, focusing on budget indicators and key tasks for performance evaluation[150]. - The company is committed to strengthening financial management and budget control, focusing on dynamic management and precise quantification of indicators[100]. - The company has implemented changes in accounting policies effective from January 1, 2023, impacting the recognition of deferred tax assets and liabilities[176].

证券代码：600129 证券简称：太极集团 公告编号：2023-64 重庆太极实业（集团）股份有限公司 关于盐酸氟西汀胶囊通过仿制药一致性评价的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司）全资 子公司太极集团重庆涪陵制药厂有限公司（以下简称：涪陵制药厂）收到 国家药品监督管理局关于盐酸氟西汀胶囊的《药品补充申请批准通知书》， 涪陵制药厂盐酸氟西汀胶囊通过仿制药质量和疗效一致性评价。现将相关 情况公告如下： 1 药品名称 盐酸氟西汀胶囊 剂 型 胶囊剂 申请事项 仿制药质量和疗效一致性评价 规 格 20mg（按 C17H18F3NO 计） 注册分类 化学药品 药品注册标准编号 YBH19472023 原药品批准文号 国药准字 H20094152 上市许可持有人 太极集团重庆涪陵制药厂有限公司 生产企业 西南药业股份有限公司 审批结论 根据《中华人民共和国药品管理法》、《国务院关于 改革药品医疗器械审评审批制度的意见》（国发 〔2015〕44 号）、《关于仿制药 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-63 重庆太极实业（集团）股份有限公司 关于归还使用闲置募集资金补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 2023 年 8 月 23 日，重庆太极实业（集团）股份有限公司（以 下简称：公司）第十届董事会第十五次会议审议通过了《关于使用 部分闲置募集资金暂时用于补充流动资金的议案》，同意公司使用 不超过 25,000 万元闲置募集资金暂时用于补充流动资金，使用期限 为自董事会审议通过之日起不超过 12 个月。具体内容详见公司刊登 于《中国证券报》《上海证券报》《证券时报》《证券日报》及上 海证券交易所网站（www.sse.com.cn）的公告（公告编号：2023- 38；2023-41）。 2023 年 12 月 1 日，公司提前归还用于暂时补充流动资金的闲 置募集资金 3,000 万元至公司募集资金专用账户，用于支付募投项 目资金，本次归还的募集资金使用期限未超过 12 个月。公司已将归 还情况通知了保荐机构东方证券承销保荐有限公司及保 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-60 重庆太极实业（集团）股份有限公司 关于公司控股股东股权解押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示: ● 重庆太极实业（集团）股份有限公司（以下简称：公司）控股 股东太极集团有限公司(以下简称：太极有限)持有公司股份 15,381.24 万股，占公司总股本的 27.62%。本次解除质押及再次质押 后,太极有限及其一致行动人累计质押股份 4,700.00 万股，占其所持 股份的 30.56%，占公司总股本的 8.44%。 公司于2023年10月31日接太极有限通知，获悉其所持有公司部分 股份办理解除质押和再次质押登记手续，具体事项如下： 1 股东名称 太极集团有限公司 本次解质股份 800.00万股 占其所持股份比例 5.20% 占公司总股本比例 1.44% 解质时间 2023年10月30日 持股数量 15,381.24万股 持股比例 27.62% 剩余被质押股份数量 3,900.00万股 剩余被质押股份数量占其所持股份比例 ...